HIF/Hypoxia-Reporter Cell Lines
Application
Hypoxia/Hypoxia-inducible factor 1 (HIF-1) inducible luciferase/LacZ reporter cell lines.
Key Benefit
Expression of luciferase and beta-galactosidase in response to hypoxia treatment.
Technical Summary
Emory University researcher, Erwin Van Meir, has made HIF/hypoxia reporter cell lines by stably transfecting the cells with pBIGL-V6R-HRE-Luc/LacZ reporter construct. The cell lines can be used to monitor transcriptional activity of the reporter in response to hypoxia or HIF transcriptional activity. The reporter activates both luciferase and b-galactosidase expression.
- LN229 human glioblastoma : pBIGL-V6R-HRE-Luc/LacZ
- Mel290 human uveal melanoma : pBIGL-V6R-HRE-Luc/LacZ
- B16LS9 mouse melanoma : pBIGL-V6R-HRE-Luc/LacZ
- 9L rat glioma : pBIGL-V6R-HRE-Luc/LacZ
Developmental Stage
Cell lines are developed and available for license.
Publications
Post, D.E. et al. (2001). Gene Therapy, 8, 1801-1807.
Yin S. et al. (2012). Cancer Research, 18, 6623-6633.
Patent Information
| App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Patent Status |
|
|
